While LBC is typically estrogen receptor-positive and historically considered to have a favorable prognosis, emerging molecular evidence suggests that CDH1 loss contributes to distinct clinical behavior. The gene discussed is ESR1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.